Regulus Therapeutics Inc Cash Flow Conversion Efficiency
Regulus Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Regulus Therapeutics Inc (RGLS) has a cash flow conversion efficiency ratio of -0.154x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.61 Million) by net assets ($69.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Regulus Therapeutics Inc (2010–2024)
Cash flow conversion efficiency of Regulus Therapeutics Inc from 2010 to 2024. This chart illustrates how Regulus Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Regulus Therapeutics Inc share price for real-time trading data and today's change.
Regulus Therapeutics Inc Cash Flow Conversion Ratio Explained
Regulus Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Regulus Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Regulus Therapeutics Inc ranked by their cash flow conversion efficiency. Also see RGLS company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ningbo Marine Co Ltd
SHG:600798
|
0.040x |
|
Tifico Fiber Indonesia Tbk
JK:TFCO
|
0.022x |
|
DL Holdings CO. LTD.
KO:000210
|
0.026x |
|
Diversified Royalty Corp
TO:DIV
|
0.016x |
|
Atom Hoteles Socimi
MC:YATO
|
0.028x |
|
GSP Automotive Group Wenzhou Co Ltd
SHG:605088
|
0.021x |
|
Beijing Hualian Department Store Co Ltd
SHE:000882
|
0.029x |
|
Hunan Hansen Pharmaceutical Co Ltd
SHE:002412
|
0.022x |
Annual Cash Flow Conversion Efficiency for Regulus Therapeutics Inc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Regulus Therapeutics Inc from 2010 to 2024. Review RGLS free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $76.41 Million | $-41.67 Million | -0.545x | +56.83% |
| 2023-12-31 | $21.19 Million | $-26.77 Million | -1.263x | -64.77% |
| 2022-12-31 | $33.29 Million | $-25.53 Million | -0.767x | -74.65% |
| 2021-12-31 | $54.96 Million | $-24.13 Million | -0.439x | +8.85% |
| 2020-12-31 | $26.03 Million | $-12.54 Million | -0.482x | +51.36% |
| 2019-12-31 | $20.02 Million | $-19.82 Million | -0.990x | -113.40% |
| 2018-12-31 | $-5.85 Million | $-43.27 Million | 7.392x | +542.92% |
| 2017-12-31 | $35.22 Million | $-58.77 Million | -1.669x | -64.53% |
| 2016-12-31 | $56.08 Million | $-56.88 Million | -1.014x | -152.44% |
| 2015-12-31 | $124.08 Million | $-49.86 Million | -0.402x | -34.26% |
| 2014-12-31 | $132.01 Million | $-39.51 Million | -0.299x | +1.27% |
| 2013-12-31 | $93.46 Million | $-28.33 Million | -0.303x | -115.83% |
| 2012-12-31 | $62.09 Million | $-8.72 Million | -0.140x | -138.69% |
| 2011-12-31 | $-41.49 Million | $-15.06 Million | 0.363x | -76.41% |
| 2010-12-31 | $8.00 Million | $12.31 Million | 1.539x | -- |
About Regulus Therapeutics Inc
Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target o… Read more